tiprankstipranks
Trending News
More News >
Molecular Partners (MOLN)
NASDAQ:MOLN
US Market

Molecular Partners (MOLN) Stock Forecast & Price Target

Compare
30 Followers
See the Price Targets and Ratings of:

MOLN Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Molecular
Partners
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MOLN Stock 12 Month Forecast

Average Price Target

$10.00
▲(145.10% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is $10.00 with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 145.10% change from the last price of $4.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","13":"$13","4.75":"$4.75","7.5":"$7.5","10.25":"$10.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.75,7.5,10.25,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.02,4.633846153846154,5.247692307692308,5.861538461538461,6.475384615384615,7.0892307692307694,7.703076923076923,8.316923076923077,8.930769230769231,9.544615384615385,10.15846153846154,10.772307692307692,11.386153846153846,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.02,4.4799999999999995,4.9399999999999995,5.3999999999999995,5.859999999999999,6.32,6.779999999999999,7.24,7.699999999999999,8.16,8.620000000000001,9.08,9.54,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.02,4.326153846153845,4.632307692307692,4.938461538461538,5.2446153846153845,5.55076923076923,5.856923076923076,6.163076923076923,6.469230769230769,6.775384615384615,7.081538461538461,7.387692307692308,7.693846153846153,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$10.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on MOLN
LifeSci Capital
LifeSci Capital
$12
Buy
194.12%
Upside
Reiterated
12/08/25
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular PartnersKey Takeaways: MOLN provided an update on the Phase 1/2a study of MP0533, a CD33xCD123xCD70xCD3 tetraspecific TCE in R/R AML or MDS, through a poster presentaon.
Clear Street Analyst forecast on MOLN
Clear Street
Clear Street
$8
Buy
96.08%
Upside
Reiterated
12/08/25
Molecular Partners (MOLN) Receives a Buy from Clear Street
J.P. Morgan Analyst forecast on MOLN
J.P. Morgan
J.P. Morgan
$4.5$4
Hold
-1.96%
Downside
Reiterated
09/03/25
Molecular Partners price target lowered to $4 from $4.50 at JPMorganMolecular Partners price target lowered to $4 from $4.50 at JPMorgan
Leerink Partners Analyst forecast on MOLN
Leerink Partners
Leerink Partners
$9
Buy
120.59%
Upside
Reiterated
08/25/25
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
TD Cowen
$17
Buy
316.67%
Upside
Reiterated
03/14/25
Molecular Partners: Strategic Positioning and Innovative Platforms Drive Buy Rating in Oncology Space
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on MOLN
LifeSci Capital
LifeSci Capital
$12
Buy
194.12%
Upside
Reiterated
12/08/25
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular PartnersKey Takeaways: MOLN provided an update on the Phase 1/2a study of MP0533, a CD33xCD123xCD70xCD3 tetraspecific TCE in R/R AML or MDS, through a poster presentaon.
Clear Street Analyst forecast on MOLN
Clear Street
Clear Street
$8
Buy
96.08%
Upside
Reiterated
12/08/25
Molecular Partners (MOLN) Receives a Buy from Clear Street
J.P. Morgan Analyst forecast on MOLN
J.P. Morgan
J.P. Morgan
$4.5$4
Hold
-1.96%
Downside
Reiterated
09/03/25
Molecular Partners price target lowered to $4 from $4.50 at JPMorganMolecular Partners price target lowered to $4 from $4.50 at JPMorgan
Leerink Partners Analyst forecast on MOLN
Leerink Partners
Leerink Partners
$9
Buy
120.59%
Upside
Reiterated
08/25/25
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
TD Cowen
$17
Buy
316.67%
Upside
Reiterated
03/14/25
Molecular Partners: Strategic Positioning and Innovative Platforms Drive Buy Rating in Oncology Space
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Molecular Partners

1 Month
xxx
Success Rate
2/7 ratings generated profit
29%
Average Return
-3.19%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 28.57% of your transactions generating a profit, with an average return of -3.19% per trade.
3 Months
xxx
Success Rate
2/7 ratings generated profit
29%
Average Return
-3.23%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -3.23% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
3/7 ratings generated profit
43%
Average Return
+1.11%
reiterated a buy rating 9 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +1.11% per trade.
2 Years
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
+1.11%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +1.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MOLN Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
2
3
2
4
Buy
0
0
0
0
0
Hold
13
18
24
22
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
20
27
24
16
In the current month, MOLN has received 4 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. MOLN average Analyst price target in the past 3 months is 10.00.
Each month's total comprises the sum of three months' worth of ratings.

MOLN Financial Forecast

MOLN Earnings Forecast

Next quarter’s earnings estimate for MOLN is -$0.39 with a range of -$0.43 to -$0.35. The previous quarter’s EPS was -$0.69. MOLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MOLN has Performed in-line its overall industry.
Next quarter’s earnings estimate for MOLN is -$0.39 with a range of -$0.43 to -$0.35. The previous quarter’s EPS was -$0.69. MOLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MOLN has Performed in-line its overall industry.

MOLN Sales Forecast

Next quarter’s sales forecast for MOLN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MOLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MOLN has Performed in-line its overall industry.
Next quarter’s sales forecast for MOLN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MOLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MOLN has Performed in-line its overall industry.

MOLN Stock Forecast FAQ

What is MOLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Molecular Partners’s 12-month average price target is 10.00.
    What is MOLN’s upside potential, based on the analysts’ average price target?
    Molecular Partners has 145.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MOLN a Buy, Sell or Hold?
          Molecular Partners has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Molecular Partners’s price target?
            The average price target for Molecular Partners is 10.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $8.00. The average price target represents 145.10% Increase from the current price of $4.08.
              What do analysts say about Molecular Partners?
              Molecular Partners’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of MOLN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.